Evidence map›Paper›PMID 35091584›Full record

ArticleScientific reports2022

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis.

C Meurot, C Martin, L Sudre, J Breton, C Bougault, R Rattenbach, K Bismuth, C Jacques, F Berenbaum

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05419856 (A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of 4P004 Versus Placebo Injected in the Target Knee of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index), which is not on this map. Cited by 86 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 4 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05419856 phase1completednot on this map

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of 4P004 Versus Placebo Injected in the Target Knee of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index

TypeinterventionalSponsor4Moving BiotechRan2022 to 2023Enrolled34ConditionsKnee OsteoarthritisArms4P-004, Placebo
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Emerging therapies for knee osteoarthritis.Nature reviews. Rheumatology · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

C Meurot4P-Pharma, Lille, France.
C Martin4P-Pharma, Lille, France.
L Sudre4P-Pharma, Lille, France.
J Breton4P-Pharma, Lille, France.
C BougaultSorbonne University, INSERM CRSA St-Antoine, Paris, France.
R Rattenbach4P-Pharma, Lille, France.
K Bismuth4P-Pharma, Lille, France.
C JacquesSorbonne University, INSERM CRSA St-Antoine, Paris, France.
F Berenbaum4Moving Biotech, Lille, France. francis.berenbaum@aphp.fr.
Paris Biotech Santé · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a common disabling disease worldwide, with no effective and safe disease-modifying drugs (DMOAD) in the market. However, studies suggest that drugs, such as liraglutide, which possess strong potential in decreasing low-grade systemic inflammation may be effective in treating OA. Therefore, the aim of this study was to examine the anti-inflammatory, analgesic, and anti-degradative effects in OA using in vitro and in vivo experiments. The results showed that intra-articular injection of liraglutide alleviated pain-related behavior in in vivo sodium monoiodoacetate OA mouse model, which was probably driven by the GLP-1R-mediated anti-inflammatory activity of liraglutide. Moreover, liraglutide treatment significantly decreased IL-6, PGE

Indexed as

AnalgesicsAnti-Inflammatory AgentsGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideOsteoarthritisAnimalsChondrocytesDisease Models, AnimalMacrophagesMaleMiceMice, Inbred C57BLNitric OxideRAW 264.7 CellsAnalgesicsAnti-Inflammatory AgentsGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideNitric Oxide

Identifiers

PMID35091584
PMCPMC8799666
OpenAlexW4210711301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.